T2 Biosystems, Inc. – NASDAQ:TTOO
T2 Biosystems stock price today
$0.013
-0.41
-97.06%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
T2 Biosystems stock price monthly change
-92.26%
month
T2 Biosystems stock price quarterly change
-92.26%
quarter
T2 Biosystems stock price yearly change
-91.76%
year
T2 Biosystems key metrics
Market Cap | 7.36M |
Enterprise value | 48.89M |
P/E | -0.04 |
EV/Sales | 1.37 |
EV/EBITDA | -0.58 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -16.03 |
Revenue | 7.17M |
EBITDA | -48.20M |
Income | -45.64M |
Revenue Q/Q | -0.81% |
Revenue Y/Y | -58.15% |
Profit margin | -273.24% |
Oper. margin | -239.98% |
Gross margin | 8.64% |
EBIT margin | -239.98% |
EBITDA margin | -671.75% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeT2 Biosystems stock price history
T2 Biosystems stock forecast
T2 Biosystems financial statements
| Jun 2023 | 1.96M | -6.34M | -323.17% |
|---|---|---|---|
| Sep 2023 | 1.47M | -15.42M | -1047.89% |
| Dec 2023 | 1.67M | -10.34M | -615.84% |
| Mar 2024 | 2.06M | -13.53M | -656.67% |
| Mar 2024 | 2.06M | -13.53M | -656.67% |
|---|---|---|---|
| Sep 2025 | 6.21M | -1.09M | -17.62% |
| Oct 2025 | 6.2M | -1.63M | -26.3% |
| Dec 2025 | 7.4M | -1.37M | -18.59% |
Analysts Price target
Financials & Ratios estimates
| 2023-03-13 | -2.8945 | -3.5 |
|---|
| Jun 2023 | 37130000 | 73.55M | 198.1% |
|---|---|---|---|
| Sep 2023 | 43281000 | 62.51M | 144.44% |
| Dec 2023 | 34797000 | 62.83M | 180.57% |
| Mar 2024 | 24755000 | 62.52M | 252.59% |
| Jun 2023 | -12.38M | -33K | 18.38M |
|---|---|---|---|
| Sep 2023 | -13.39M | -13K | 21.64M |
| Dec 2023 | -9.41M | -26K | 812K |
| Mar 2024 | -11.68M | 0 | 2.20M |
T2 Biosystems alternative data
| Aug 2023 | 158 |
|---|---|
| Sep 2023 | 158 |
| Oct 2023 | 158 |
| Nov 2023 | 158 |
| Dec 2023 | 158 |
| Jan 2024 | 158 |
| Feb 2024 | 158 |
| Mar 2024 | 158 |
| Apr 2024 | 158 |
| May 2024 | 113 |
| Jun 2024 | 113 |
| Jul 2024 | 113 |
T2 Biosystems other data
9.63%
-1.94%
of TTOO is owned by hedge funds
15.30M
-3.90M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 0 | 1292 |
| Feb 2023 | 0 | 16733 |
| Mar 2023 | 0 | 239 |
| Sep 2023 | 0 | 43134705 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SPERZEL JOHN J III director, officer.. | Common Stock | 67 | N/A | N/A | ||
Option | SPERZEL JOHN J III director, officer.. | Restricted Stock Units | 67 | N/A | N/A | ||
Option | SPRAGUE JOHN M officer: Chief Financial Officer | Common Stock | 29 | N/A | N/A | ||
Option | SPRAGUE JOHN M officer: Chief Financial Officer | Restricted Stock Units | 29 | N/A | N/A | ||
Option | GIBBS MICHAEL TERRENCE officer: General Counsel | Common Stock | 29 | N/A | N/A | ||
Option | GIBBS MICHAEL TERRENCE officer: General Counsel | Restricted Stock Units | 29 | N/A | N/A | ||
Option | GIBBS MICHAEL TERRENCE officer: General Counsel | Common Stock | 40 | N/A | N/A | ||
Option | GIBBS MICHAEL TERRENCE officer: General Counsel | Restricted Stock Units | 40 | N/A | N/A | ||
Option | SPRAGUE JOHN M officer: Chief Financial Officer | Common Stock | 40 | N/A | N/A | ||
Option | SPERZEL JOHN J III director, officer.. | Common Stock | 160 | N/A | N/A |
| Patent |
|---|
Application Filling date: 10 Sep 2019 Issue date: 8 Sep 2022 |
Application Filling date: 5 Apr 2022 Issue date: 21 Jul 2022 |
Application Filling date: 24 Aug 2021 Issue date: 19 May 2022 |
Grant Filling date: 21 Jan 2016 Issue date: 10 May 2022 |
Application Filling date: 6 Apr 2021 Issue date: 17 Mar 2022 |
Grant Filling date: 12 Jan 2017 Issue date: 24 Aug 2021 |
Application Filling date: 28 Jul 2020 Issue date: 17 Jun 2021 |
Application Filling date: 25 Mar 2020 Issue date: 18 Feb 2021 |
Application Filling date: 12 Apr 2017 Issue date: 7 Jan 2021 |
Application Filling date: 17 May 2018 Issue date: 17 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 12 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. John J. Sperzel III, B.Sc. (1963) Chairman & Chief Executive Officer | $897,270 |
| Mr. Alec J. Barclay (1980) Chief Operations Officer | $575,550 |
-
What's the price of T2 Biosystems stock today?
One share of T2 Biosystems stock can currently be purchased for approximately $0.01.
-
When is T2 Biosystems's next earnings date?
Unfortunately, T2 Biosystems's (TTOO) next earnings date is currently unknown.
-
Does T2 Biosystems pay dividends?
No, T2 Biosystems does not pay dividends.
-
How much money does T2 Biosystems make?
T2 Biosystems has a market capitalization of 7.36M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 67.75% to 7.19M US dollars. T2 Biosystems made a loss 50.08M US dollars in net income (profit) last year or -$3.5 on an earnings per share basis.
-
What is T2 Biosystems's stock symbol?
T2 Biosystems, Inc. is traded on the NASDAQ under the ticker symbol "TTOO".
-
What is T2 Biosystems's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of T2 Biosystems?
Shares of T2 Biosystems can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are T2 Biosystems's key executives?
T2 Biosystems's management team includes the following people:
- Mr. John J. Sperzel III, B.Sc. Chairman & Chief Executive Officer(age: 62, pay: $897,270)
- Mr. Alec J. Barclay Chief Operations Officer(age: 45, pay: $575,550)
-
How many employees does T2 Biosystems have?
As Jul 2024, T2 Biosystems employs 113 workers, which is 28% less then previous quarter.
-
When T2 Biosystems went public?
T2 Biosystems, Inc. is publicly traded company for more then 11 years since IPO on 7 Aug 2014.
-
What is T2 Biosystems's official website?
The official website for T2 Biosystems is t2biosystems.com.
-
Where are T2 Biosystems's headquarters?
T2 Biosystems is headquartered at 101 Hartwell Avenue, Lexington, MA.
-
How can i contact T2 Biosystems?
T2 Biosystems's mailing address is 101 Hartwell Avenue, Lexington, MA and company can be reached via phone at +7 817614646.
T2 Biosystems company profile:
T2 Biosystems, Inc.
t2biosystems.comExchange:
NASDAQ
Full time employees:
113
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
101 Hartwell Avenue
Lexington, MA 02421
Lexington, MA 02421
CIK: 0001492674
ISIN: US89853L3024
CUSIP: 89853L104
